---
figid: PMC7730041__ijms-21-09020-g005
figtitle: The molecular pathways responsible for PGE2-mediated inhibition (PGE2 concentration
  > 10 µmol/L, via EP2- and EP4-receptors) and stimulation (PGE2 concentration < 10
  µmol/L, via EP3- receptor) of platelet activation
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC7730041
filename: ijms-21-09020-g005.jpg
figlink: pmc/articles/PMC7730041/figure/ijms-21-09020-f005/
number: F5
caption: Schematic overview of the molecular pathways responsible for PGE2-mediated
  inhibition (PGE2 concentration > 10 µmol/L, via EP2- and EP4-receptors) and stimulation
  (PGE2 concentration < 10 µmol/L, via EP3- receptor) of platelet activation. The
  inhibitory pathways comprise activation of AC and increase of cAMP. This induces
  CalDAG-GEFI, EPAC and PKA signaling, which results in the phosphorylation of different
  proteins as well as (plasma membrane) receptors and the downregulation of calcium
  mobilization. Processes inducing platelet activation comprise downregulation of
  AC and upregulation of PLC. These processes result in the reduction of cAMP and
  in an elevated calcium mobilization and secretion through DAG and IP3 activation.
  The EP3- and P2Y12-receptors share the Gipathway. Through this common pathway, PGE2
  can potentiate the P2Y12-receptor-mediated and ADP-induced AC inhibition and, furthermore,
  compensate P2Y12 inhibition to a certain extent.
papertitle: 'Effect of Prostanoids on Human Platelet Function: An Overview.'
reftext: Steffen Braune, et al. Int J Mol Sci. 2020 Dec;21(23):9020.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.6674001
figid_alias: PMC7730041__F5
figtype: Figure
redirect_from: /figures/PMC7730041__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7730041__ijms-21-09020-g005.html
  '@type': Dataset
  description: Schematic overview of the molecular pathways responsible for PGE2-mediated
    inhibition (PGE2 concentration > 10 µmol/L, via EP2- and EP4-receptors) and stimulation
    (PGE2 concentration < 10 µmol/L, via EP3- receptor) of platelet activation. The
    inhibitory pathways comprise activation of AC and increase of cAMP. This induces
    CalDAG-GEFI, EPAC and PKA signaling, which results in the phosphorylation of different
    proteins as well as (plasma membrane) receptors and the downregulation of calcium
    mobilization. Processes inducing platelet activation comprise downregulation of
    AC and upregulation of PLC. These processes result in the reduction of cAMP and
    in an elevated calcium mobilization and secretion through DAG and IP3 activation.
    The EP3- and P2Y12-receptors share the Gipathway. Through this common pathway,
    PGE2 can potentiate the P2Y12-receptor-mediated and ADP-induced AC inhibition
    and, furthermore, compensate P2Y12 inhibition to a certain extent.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ac
  - ATPsynbeta
  - Atpalpha
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Mp
  - Amph
  - Mpe
  - Act5C
  - Act42A
  - Act57B
  - Act79B
  - Act88F
  - Act87E
  - ena
  - sqh
  - Mhc
  - Mlc2
  - scb
  - ca
  - gg
  - Ggamma1
  - Ggamma30A
  - norpA
  - sl
  - Plc21C
  - adp
  - ATP8A2
  - RASGRP1
  - RASGRP2
  - APRT
  - MFAP1
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - AOC1
  - SHBG
  - VASP
  - TNFSF14
  - MYH14
  - MYO6
  - MYO10
  - MYO16
  - MYO19
  - MYH1
  - MYH10
  - MYH11
  - MYH13
  - MYH15
  - MYH16
  - MYH2
  - MYH3
  - MYH4
  - MYH6
  - MYH7
  - MYH7B
  - MYH8
  - MYH9
  - MYO1A
  - MYO1B
  - MYO1C
  - MYO1D
  - MYO1E
  - MYO1F
  - MYO1G
  - MYO1H
  - MYO3A
  - MYO3B
  - MYO5A
  - MYO5B
  - MYO5C
  - MYO7A
  - MYO7B
  - MYO9A
  - MYO9B
  - MYO15A
  - MYO15B
  - MYO18A
  - MYO18B
  - MYL1
  - MYL3
  - MYL4
  - MYL6
  - MYL6B
  - MYL10
  - MYL12A
  - MYL12B
  - MYL2
  - MYL5
  - MYL7
  - MYL9
  - MYL11
  - COL6A1
  - COL6A2
  - COL6A3
  - COL6A5
  - COL6A6
  - COL7A1
  - COL8A1
  - COL8A2
  - COL9A1
  - COL9A2
  - COL9A3
  - COL10A1
  - COL11A1
  - COL11A2
  - COL12A1
  - COL13A1
  - COL14A1
  - COL15A1
  - COL16A1
  - COL17A1
  - COL18A1
  - COL19A1
  - COL20A1
  - COL21A1
  - COL22A1
  - COL23A1
  - COL24A1
  - COL25A1
  - COL26A1
  - COL27A1
  - COL28A1
  - COL1A1
  - COL1A2
  - COL4A1
  - COL4A2
  - COL4A3
  - COL4A4
  - COL4A5
  - COL4A6
  - COL5A1
  - COL5A2
  - COL5A3
  - P2RY12
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - GNG10
  - GNG11
  - GNG12
  - GNG13
  - GNG2
  - GNG3
  - GNG4
  - GNG5
  - GNG7
  - GNG8
  - GNGT1
  - GNGT2
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - WDTC1
  - PGE2
  - ATP
  - Calcium
  - guanine nucleotide
  - RAP16
  - Dlacylglycerol
  - ADP
  - Inositol trisphosphate
  - Ca2+
  - platelet aggregation
---
